中国医学科学院学报

高级检索
中国医学科学院学报

中国医学科学院学报 ›› 2009, Vol. 31 ›› Issue (5): 639-643.doi: 10.3881/j.issn.1000-503X.2009.05.029

• 综述 • 上一篇    下一篇

Castleman病的发病机制和治疗进展

韩潇;周道斌   

  1. 中国医学科学院北京协和医学院北京协和医院血液内科,北京 100730
  • 收稿日期:2009-04-23 修回日期:1900-01-01 出版日期:2009-10-30 发布日期:2009-10-30
  • 通讯作者: 周道斌

Advances in Etiology and Management of Castleman’s Disease

HAN Xiao;ZHOU Dao-bin   

  1. Department of Hematology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China
  • Received:2009-04-23 Revised:1900-01-01 Online:2009-10-30 Published:2009-10-30
  • Contact: ZHOU Dao-bin

摘要: 摘要:Castleman病(CD)是一种少见的淋巴组织增殖性疾病,病因可能与病毒感染、细胞因子调节异常和血管增生等有关。近年研究发现,人类疱疹病毒(HHV)-8感染和白细胞介素(IL)-6过度表达在CD的发病机制中发挥重要作用。治疗方法包括手术切除、放疗、化疗、抗病毒治疗和靶向治疗等。多中心型CD目前尚无标准治疗方法,总体疗效欠佳。新式治疗中抗HHV-8病毒治疗效果不明确,抗CD20单抗和抗IL-6受体单抗已有良好疗效的报道,沙利度胺和硼替佐米等也初见疗效。

关键词: Castleman病, 病因, 治疗, 人类疱疹病毒-8, 白细胞介素-6, 利妥昔单抗, tocilizumab

Abstract: ABSTRACT:Castleman’s disease (CD) is a rare lymphoproliferative disorder. The etiology of CD may involve viral infection,abnormal modulation of cytokines, and angiogenesis. Human herpes virus (HHV)-8 infection and interleukin-6(IL-6) overexpression may play key roles in the development of CD. Treatment options include surgical excision,radiation therapy, chemotherapy, antiviral therapy, and targeted therapy. No standardized treatment has been established for multicentric CD and the treatment efficacy usually is poor. Among newly available agents, the effectiveness of antiviral therapy against HHV-8 is unclear; anti-CD20 and anti-IL-6 receptor monoclonal antibodies have shown promising efficacy; thalidomide and bortezomib have shown their initial efficacy.

Key words: castleman’s disease, etiolocy, treatment, duman derpes virus-8, interleukin-6, rituximab